Amgen’s autoimmune drug succeeds in late-stage trial

Amgen reports a Phase 3 win with Sjögren’s drug candidate

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

Amgen’s autoimmune drug succeeds in late-stage trial

Sept 22 (Reuters) - Amgen said on Tuesday its experimental drug to treat an autoimmune disease that ​attacks the body's moisture-producing ‌glands met the main goal of reducing disease activity in a late-stage trial. Here are some details: • The drug d...

Amgen reports Phase 3 dazodalibep Sjögren's win

OASIZ 301 met its systemic disease measure, but Amgen did not disclose the treatment gap; a second Phase 3 study is due to finish this year.

Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Amgen (AMGN) Stock Surges 4% on Breakthrough Sjögren's Disease Trial Results

Key Highlights Shares of Amgen rose approximately 4% during premarket hours Tuesday following encouraging Phase 3 data for dazodalibep in treating Sjögren’s disease The OASIZ 301 clinical trial achieved its primary goal, demonstrating statistically significant improvements in systemic disease severity at the 48-week mark Positive changes in patient outcomes emerged as soon as Week 4 and remained consistent throughout the complete 48-week trial …

Amgen (AMGN) Stock Pops 4% as Sjögren’s Drug Could Be First of Its Kind

TLDR Amgen stock jumped roughly 4% in premarket trading Tuesday after positive Phase 3 trial results for dazodalibep in Sjögren’s disease The OASIZ 301 study met its primary endpoint, showing statistically meaningful improvement in systemic disease activity at Week 48 Improvements were seen as...